• The modern features of pathogenesis1induced prevention of preeclampsia 

The modern features of pathogenesis1induced prevention of preeclampsia 

PERINATOLOGIYA I PEDIATRIYA.2016.1(65):46-50;doi 10.15574/PP.2016.65.46 
 

The modern features of pathogenesis1induced prevention of preeclampsia 
 

Konkov D. G., Bulavenko O. V., Dudnik V. M., Buran V. V.

Vinnytsya National Pirogov Memorial Medical University, Vinnytsya, Ukraine 
 

Purpose — the assessment of clinical effectiveness of preventive therapy in pregnant women with high risk of preeclampsia. 
 

Patients and methods. In the comparative study on the effectiveness of preventive therapy were participated 110 pregnant women with decidual vasculopathy and endothelial dysfunction, which had high risk of preeclampsia. We investigated the clinical efficacy for medications that containing 75 mg of acetylsalicylic acid and L-arginine. 
 

Results. The results of the study have shown that use of preventive treatment (L-arginine and acetylsalicylic acid) from 12 weeks, among pregnant women with high risk of preeclampsia, led to a significant decrease of perinatal loss, reduction of clinical manifestations of preeclampsia, preterm delivery, malformations and malpresentation of the placenta, cases of asphyxia of the newborns, perinatal CNS lesions and intra-ventricular hemorrhage. 
 

Conclusions. Clinical effectiveness of preventive treatment (L-arginine and ASA) among pregnant women with high risk of preeclampsia was proven. Furthermore it was recognized clinically effective use of 75 mg of ASA from 12 weeks of pregnancy. No side effects of drugs in the study were noted. 
 

Key words: preeclampsia, endothelial dysfunction, acetylsalicylic acid, L-arginine. 
 

REFERENCES

1. Konkov DG. 2013. Vyibor skriningovogo metoda diagnostiki gestatsionnoy endoteliopatii. Mezhdunarodnaya nauchno-prakticheskaya konferentsiya «Aktualnyie voprosyi sovremennoy meditsinyi», g. Novosibirsk, 14 yanvarya 2013 g. Novosibirsk: 9—13.

2. Konkov DG, Protsepko AA. 2009. Endotelialnaya disfunktsiya v geneze nevyinashivaniya beremennosti. Problemyi, dostizheniya i perspektivyi razvitiya mediko-biologicheskih nauk i prakticheskogo zdravohraneniya. 145; ІІ: 157—160.

3. Zaporozhan VM, Halych SR, Konkov DH. 2012. Pat. № 71862 A Ukraina, MPK G01N 33/48. Sposib doklinichnoi diahnostyky hestatsiinoi endoteliopatii. Zaiavnyk ta patentovlasnyk Vinnytskyi natsionalnyi medychnyi universytet imeni M.I. Pyrohova. №U 201201377; zaiavl. 09.02.2012; opubl. 25.07.2012, Biul. № 14.

4. Zaporozhan VM, Konkov DH, Halych SR, Lutsker OL. 2013. Pat. № 77984 A Ukraina, MPK A61V 10/00. Sposib neinvazyvnoi diahnostyky funktsionalnoho stanu endoteliiu pry vahitnosti. Zaiavnyk ta patentovlasnyk Vinnytskyi natsionalnyi medychnyi universytet imeni M.I. Pyrohova. № U 2012074361; zaiavl. 19.06.2012; opubl. 11.03.2013, Biul. № 5.

5. Zainul Rashid MR, Jing Fen Lim, Noorfaizahtul Hanim M Nawawi et al. 2014. A pilot study to determine whether progestogen supplementation using dydrogesterone during the first trimester will reduce the incidence of gestational hypertension in primigravidae. Gynecol Endocrinol. 30(3): 217—220. http://dx.doi.org/10.3109/09513590.2013.860960; PMid:24552449

6. Shunping Gui, Jin Jia, Xiaoyu Niu et al. 2014. Arginine supplementation for improving maternal and neonatal out-comes in hypertensive disorder of pregnancy: A systematic review. Journal of the Renin-Angiotensin-Aldosterone System. 15(1): 88—96. http://dx.doi.org/10.1177/1470320313475910; PMid:23435582

7. Bujold E, Roberge S, Demers S et al. 2012. Aspirin administration for prevention of adverse pregnancy outcomes. Fetal and Maternal Medicine Review. 23; Iss 3—4: 187—200. http://dx.doi.org/10.1017/S0965539512000101

8. Villa P, Kajantie E, Raikkonen K et al. 2013. Aspirin in the prevention of preeclampsia in high-risk women: a randomised placebo-controlled PREDO Trial and a meta-analysis of randomised trials. BJOG. 120(1): 64—74. http://dx.doi.org/10.1111/j.1471-0528.2012.03493.x; PMid:23126307

9. Cindrova-Davies T. 2014. The therapeutic potential of antioxidants, ER chaperones, NO and H2S donors, and statins for treatment of preeclampsia. Front. Pharmacol. —— Vol. 5, Iss. 119. — P. 1—13.

10. Akolekar R, Syngelaki A, Poon L et al. 2013. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther. 34(1): 43. http://dx.doi.org/10.1159/000341264

11. Felipe Vadillo-Ortega, Otilia Perichart-Perera, Salvador Espino et al. 2011. Effect of supplementation during pregnancy with L-arginine and antioxidant vitamins in medical food on preeclampsia in high risk population: randomised controlled trial. BMJ. 342: d2901. http://dx.doi.org/10.1136/bmj.d2901; PMid:21596735 PMCid:PMC3100912

12. Augusto Henriques Fulgencio Brandao, Marcelo Araujo Cabral. 2012. Endothelial function, uterine perfusion and central flow in pregnancies complicated by preeclampsia. Arq Bras Cardiol. 13; Iss 99(4): 931—935.

13. Wang Y, Gu Y, Zhang Y, Lewis DF. 2004. Evidence of endothelial dysfunction in preeclampsia: decreased endothelial nitric oxide synthase expression is associated with increased cell permeability in endothelial cells from preeclampsia. Am J Obstet Gynecol. 190(3): 817—824. http://dx.doi.org/10.1016/j.ajog.2003.09.049

14. Hypertension in Pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstetrics & Gynecology. 2013. 122; 5: 1122—1131. PMid:24150027

15. Hypertension in Pregnancy: The Management of Hypertensive Disorders During Pregnancy. NICE Clinical Guidelines. National Collaborating Centre for Women's and Children's Health (UK). London: RCOG Press, 2011: 295.

16. Gillon TER, Pels A, von Dadelszen P et al. 2014. Hypertensive disorders of pregnancy: a systematic review of International Clinical Practice Guidelines. International Clinical Practice Guidelines. PLoS ONE 9 (12): e113715. http://dx.doi.org/10.1371/journal.pone.0113715; PMid:25436639 PMCid:PMC4249974

17. Konkov DG. 2013. Caratteristiche prevenzione dei clinici manifesti-forme endoteliopatia gestazionale. Italian Science Review. 8: 11—15.

18. Roberge S, Nicolaides KH, Demers S et al. 2013. Prevention of perinatal death and adverse perinatal outcome using low-dose aspirin: a meta-analysis. Ultrasound Obstet Gynecol. 41(5): 491—499. http://dx.doi.org/10.1002/uog.12421; PMid:23362106